APA (7th ed.) Citation

Woude, D. v. d., Trouw, L. A., Huizinga, T. W., Mil, A. H. v. d. H., Toes, R. E., Wesemael, T. J. v., . . . Hoogslag, A. T. W. (2023, October). Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open.

Chicago Style (17th ed.) Citation

Woude, Diane van der, Leendert A. Trouw, Tom WJ Huizinga, Annette HM van der Helm-van Mil, René EM Toes, Tineke J van Wesemael, Michelle D van den Beukel, Nicole V. Borggreven, and Anna Titia W. Hoogslag. "Antibodies Against Advanced Glycation End-products and Malondialdehyde-acetaldehyde Adducts Identify a New Specific Subgroup of Hitherto Patients with Seronegative Arthritis with a Distinct Clinical Phenotype and an HLA Class II Association." RMD Open Oct. 2023.

MLA (9th ed.) Citation

Woude, Diane van der, et al. "Antibodies Against Advanced Glycation End-products and Malondialdehyde-acetaldehyde Adducts Identify a New Specific Subgroup of Hitherto Patients with Seronegative Arthritis with a Distinct Clinical Phenotype and an HLA Class II Association." RMD Open, Oct. 2023.